Alaunos Therapeutics Income Statement (2009-2026) | TCRT

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)		0.40M	0.00M			2.91M	0.01M		0.00M		0.00M	0.00M	0.00M		0.00M	0.00M			0.00M
Cost of Revenue (Quarter)
Gross Profit (Quarter)
Operating items
Research & Development (Quarter)	13.57M	14.52M	8.22M	5.58M	5.94M	7.89M	5.61M	6.50M	5.19M	3.66M	0.93M	0.13M	0.18M	0.14M	-0.09M	0.35M	0.18M	0.47M	0.36M	0.43M
Selling, General & Administrative (Quarter)	9.07M	8.17M	2.10M	3.50M	3.43M	3.28M	2.92M	3.17M	3.04M	3.58M	2.43M	1.62M	0.99M	1.01M	0.84M	0.75M	0.85M	0.72M	0.55M	0.58M
Restructuring Costs (Quarter)										0.42M	0.85M
Other Operating Expenses (Quarter)			0.74M		-0.13M				-0.24M	1.01M	3.74M
Operating Expenses (Quarter)	22.64M	22.69M	11.05M	9.09M	9.23M	11.18M	8.53M	9.67M	7.99M	8.66M	7.95M	1.74M	1.17M	1.15M	0.76M	1.09M	1.04M	1.19M	0.91M	1.01M
Operating Income (Quarter)	-22.64M	-22.30M	-11.05M	-9.09M	-9.23M	-8.26M	-8.52M	-9.67M	-7.98M	-8.66M	-7.95M	-1.74M	-1.17M	-1.15M	-0.76M	-1.09M	-1.04M	-1.19M	-0.91M	-1.01M
EBIT (Quarter)	-22.64M	-22.30M	-11.05M	-9.09M	-9.23M	-8.26M	-8.52M	-9.67M	-7.98M	-8.66M	-7.95M	-1.74M	-1.17M	-1.15M	-0.76M	-1.09M	-1.04M	-1.19M	-0.91M	-1.01M
Non-operating items
Interest & Investment Income (Quarter)
Other Non Operating Income (Quarter)	-0.03M	0.01M	0.00M	-0.02M	0.04M	0.25M	0.25M	0.48M	0.28M	0.19M	0.11M	0.06M	0.04M	0.02M	0.01M	0.02M	0.02M	0.03M	0.01M	0.01M
Non Operating Income (Quarter)	-0.03M	-0.44M	-0.74M	-0.70M	0.04M	0.25M	-0.64M	0.48M	0.28M	0.19M	0.11M	0.06M	0.04M	0.02M	0.01M	0.02M	0.02M	0.03M	0.04M	0.01M
Net income details
EBT (Quarter)	-22.64M	-22.70M	-11.80M	-9.79M	-9.97M	-9.06M	-9.41M	-10.53M	-9.05M	-8.66M	-7.95M	-1.74M	-1.17M	-1.15M	-0.76M	-1.09M	-1.04M	-1.19M	-0.91M	-1.01M
Profit After Tax (Quarter)	-22.67M	-22.73M	-11.79M	-9.79M	-9.93M	-8.85M	-9.16M	-10.05M	-8.77M	-8.48M	22.62M	-1.68M	-1.13M	-1.13M	-0.74M	-1.07M	-1.05M	-1.16M	-0.89M	-1.01M
Income from Continuing Operations (Quarter)	-22.64M	-22.70M	-11.80M	-9.79M	-9.97M	-9.06M	-9.41M	-10.53M	-9.05M	-8.66M	-7.95M	-1.74M	-1.17M	-1.15M	-0.76M	-1.09M	-1.04M	-1.19M	-0.91M	-1.01M
Consolidated Net Income (Quarter)	-22.64M	-22.70M	-11.80M	-9.79M	-9.97M	-9.06M	-9.41M	-10.53M	-9.05M	-8.66M	-7.95M	-1.74M	-1.17M	-1.15M	-0.76M	-1.09M	-1.04M	-1.19M	-0.91M	-1.01M
Income towards Parent Company (Quarter)	-22.64M	-22.70M	-11.80M	-9.79M	-9.97M	-9.06M	-9.41M	-10.53M	-9.05M	-8.66M	-7.95M	-1.74M	-1.17M	-1.15M	-0.76M	-1.09M	-1.04M	-1.19M	-0.91M	-1.01M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-22.67M	-22.70M	-11.80M	-9.79M	-9.93M	-9.06M	-9.41M	-10.53M	-9.05M	-8.66M	-7.95M	-1.74M	-1.17M	-1.15M	-0.76M	-1.09M	-1.04M	-1.19M	-0.91M	-1.01M
Additional items
EPS (Basic) (Quarter)	-0.11	-0.11	-0.06	-0.05	-0.05	-0.04	-2.48	-0.63	-5.49	-5.30	-4.90	-1.05	-0.71	-0.70	-0.46	-0.67	-0.63	-0.55	-0.36	-0.59
EPS (Weighted Average and Diluted) (Quarter)	-0.11	-0.11	-0.06	-0.05	-0.05	-0.04	-2.48	-0.63	-5.49	-5.30	-4.90	-1.05	-0.71	-0.70	-0.46	-0.67	-0.63	-0.55	-0.36	-0.59
Shares Outstanding (Weighted Average) (Quarter)	214.43M	214.31M	214.40M	214.95M	214.97M	215.02M	0.15M	15.98M	1.60M	1.60M	0.15M	1.60M	1.60M	1.60M	1.60M	0.03M	0.28M	0.17M	0.11M	1.95M
Shares Outstanding (Diluted Average) (Quarter)	214.43M	214.54M	214.40M	214.95M	215.00M	215.10M	14.48M	15.98M	1.60M	1.60M	1.60M	1.60M	1.60M	1.60M	1.60M	1.60M	1.64M	1.82M	1.95M	1.95M
EBITDA (Quarter)	-22.64M	-22.30M	-11.05M	-9.09M	-9.23M	-8.26M	-8.52M	-9.67M	-7.98M	-8.66M	-7.95M	-1.74M	-1.17M	-1.15M	-0.76M	-1.09M	-1.04M	-1.19M	-0.91M	-1.01M
Interest Expenses (Quarter)		0.40M	0.74M	0.70M	0.74M	0.80M	0.89M	0.85M	1.07M

Research Tools

Developers

Alaunos Therapeutics Income Statement (2009-2026) | TCRT

Research Tools

Developers

Alaunos Therapeutics Income Statement (2009-2026) | TCRT

Create an account

Sign In

Reset Password